Agrawal Umang, Raju Reyma, Udwadia Zarir F
Associate Consultant (Infectious Diseases), PD Hinduja National Hospital and Medical Research Centre, Mumbai, India.
Clinical Assistant (Pulmonary Medicine), PD Hinduja National Hospital and Medical Research Centre, Mumbai, India.
Med J Armed Forces India. 2020 Oct;76(4):370-376. doi: 10.1016/j.mjafi.2020.08.004. Epub 2020 Sep 2.
With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19.
全球报告的病例超过1600万例,直径仅125微米的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)给我们的世界留下了不可磨灭的影响。由于对抗这种疾病的新药匮乏,医学界正在竞相寻找可能对这种新型冠状病毒有效的 repurposed 药物。最近备受关注的一种药物,尤其是在印度,是一种最初设计用于治疗流感的抗病毒药物,名为法匹拉韦。在本文中,我们试图在当前大流行的背景下对这种药物进行全面的、基于证据的综述,以阐明其在2019冠状病毒病管理中的作用。